ESCMID COVID-19 living guidelines: drug treatment and clinical management
Guidelines
Published on
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, 치료제,
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, 치료제,
[키워드] addressed
Antibiotics
approach
Bacterial
Clinical management
clinician
Colchicine
Combination
Committee
convalescent plasma
coronavirus disease
Corticosteroid
Corticosteroids
COVID-19
COVID-19 guideline
develop
Disease progression
etesevimab
Evidence
Favipiravir
Guidance
guidelines
hospitalized patients
Immunocompromised
Infection
Infectious disease
intensive care
Interferon β-1a
Intervention
involved
Ivermectin
majority
management
monoclonal antibody
Mortality
outcome
Outpatient
outpatients
oxygen
patients with COVID-19
performed
pharmacological treatment
PICO
Population
Prophylaxis
provided
question
recommendation
Remdesivir
selected
severe COVID-19
severity
Tocilizumab
Treatment
use of hydroxychloroquine
utility
was used
were given
[DOI] 10.1016/j.cmi.2021.11.007 PMC 바로가기 [Article Type] Guidelines
[DOI] 10.1016/j.cmi.2021.11.007 PMC 바로가기 [Article Type] Guidelines